CoChat
Sign Up
Cited by 23Attention Deficit Hyperactivity DisorderDevelopmental and Educational NeuropsychologySchizophrenia research and treatment

Executive Function Deficits in Children with Attention-Deficit/Hyperactivity Disorder and Improvement with Lisdexamfetamine Dimesylate in an Open-Label Study

Open access
Turgay, Atilla, Ginsberg, Lawrence, Sarkis, Elias, Jain, Rakesh, Adeyi, Ben, Gao, Joseph, Dirks, Bryan, Babcock, Thomas +4 more·2010·Journal of Child and Adolescent Psychopharmacology
DOI 10.1089/cap.2009.0110PMC PMC3005278
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To assess the effects of lisdexamfetamine dimesylate (LDX) on executive function (EF) behaviors in children with attention-deficit/hyperactivity disorder (ADHD). METHODS: This observational, open-label, 7-week, dose-optimization study of LDX (20-70 mg/day) in children with ADHD evaluated efficacy with the ADHD Rating Scale IV; safety measures included adverse events (AEs). EF was assessed with the Behavior Rating Inventory of Executive Function (BRIEF). Post hoc analyses examined BRIEF scores by sex, ADHD subtype, comorbid psychiatric symptoms, and common treatment-emergent AEs (TEAEs). ADHD Rating Scale IV scores were assessed in subjects categorized by baseline BRIEF global executive composite T scores with clinically significant (≥65) or not clinically significant (<65) impairment in EF. RESULTS: Mean (standard deviation) change from baseline to endpoint for BRIEF of -17.9 (12.5) for Global Executive Composite, -15.4 (12.6) for Behavioral Regulation Index, and -17.6 (12.3) for Metacognition Index demonstrated improvement with LDX (pooled doses; p < 0.0001 for all). Improvements in BRIEF scores were seen regardless of sex, ADHD subtype, comorbid psychiatric symptoms, common TEAEs, or baseline EF impairment category. TEAEs included decreased appetite, decreased weight, irritability, insomnia, headache, upper abdominal pain, and initial insomnia. CONCLUSIONS: Improvements were demonstrated in EF behaviors and ADHD symptoms with LDX. LDX safety profile was consistent with long-acting stimulant use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/cap.2009.0110

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In Turgay et al 7-week open-label study of 319 children aged 6-12 years with ADHD, lisdexamfetamine produced significant improvements in ADHD-RS-IV, BRIEF, and EESC scores.

    “In a 7-week, open-label study of 319 children (6–12 years) with ADHD, Turgay et al35 found significant improvements in ADHD-RS-IV, BRIEF, and EESC scores.”

    From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [35]

    The Methods describe a 7-week open-label lisdexamfetamine study in children aged 6–12 with ADHD. The Results report significant improvements in ADHD-RS-IV, BRIEF, and EESC scores, but our copy does not establish the claimed total of 319 children: it reports 317 in the safety population and 308 with baseline and endpoint BRIEF measurements. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 53 · Cited by 23

Research works printed but not linked: 41

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th. Washington, DC: American Psychiatric Association; 1994. DSM-IV. [Google Scholar]
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th. Washington, DC: American Psychiatric Association; 2000. Text Revision (DSM-IV-TR) [Google Scholar]
  3. Badre D. Cognitive control, hierarchy, and the rostro-caudal organization of the frontal lobes. Trends Cogn Sci. 2008;12:193–200. doi: 10.1016/j.tics.2008.02.004. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  4. Biederman J. Boellner SW. Childress A. Lopez FA. Krishnan S. Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007a;62:970–976. doi: 10.1016/j.biopsych.2007.04.015. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  5. Biederman J. Krishnan S. Zhang Y. McGough JJ. Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007b;29:450–463. doi: 10.1016/s0149-2918(07)80083-x. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  6. Biederman J. Monuteaux MC. Doyle AE. Seidman LJ. Wilens TE. Ferrero F, et al. Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol. 2004;72:757–766. doi: 10.1037/0022-006X.72.5.757. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  7. Biederman J. Petty CR. Doyle AE. Spencer T. Henderson CS. Marion B, et al. Stability of executive function deficits in girls with ADHD: A prospective longitudinal followup study into adolescence. Dev Neuropsychol. 2008;33:44–61. doi: 10.1080/87565640701729755. [DOI] [PubMed] [Google Scholar] · DOI
  8. Bodnar LE. Prahme MC. Cutting LE. Denckla MB. Mahone EM. Construct validity of parent ratings of inhibitory control. Child Neuropsychol. 2007;13:345–362. doi: 10.1080/09297040600899867. [DOI] [PubMed] [Google Scholar] · DOI
  9. Brown RT. Amler RW. Freeman WS. Perrin JM. Stein MT. Feldman HM, et al. American Academy of Pediatrics Committee on Quality Improvement; American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder: Treatment of attention-deficit/hyperactivity disorder: Overview of the evidence. Pediatrics. 2005;115:e749–e757. doi: 10.1542/peds.2004-2560. [DOI] [PubMed] [Google Scholar] · DOI
  10. Changeux JP. Dehaene S. Hierarchical neuronal modeling of cognitive functions: From synaptic transmission to the Tower of London. Int J Psychophysiol. 2000;35:179–187. doi: 10.1016/s0167-8760(99)00052-5. [DOI] [PubMed] [Google Scholar] · DOI
  11. Doyle AE. Executive functions in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):21–26. [PubMed] [Google Scholar]
  12. Doyle AE. Wilens TE. Kwon A. Seidman LJ. Faraone SV. Fried R, et al. Neuropsychological functioning in youth with bipolar disorder. Biol Psychiatry. 2005;58:540–548. doi: 10.1016/j.biopsych.2005.07.019. [DOI] [PubMed] [Google Scholar] · DOI
  13. DuPaul GJ. Power TJ. Anastopoulos AD. Reid R. Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998. ADHD Rating Scale—IV. [Google Scholar]
  14. Faries DE. Yalcin I. Harder D. Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:107–115. [Google Scholar]
  15. Findling RL. Childress AC. Krishnan S. McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectrums. 2008;13:614–620. doi: 10.1017/s1092852900016898. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  16. Findling RL. Ginsberg LD. Jain R. Gao J. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: An open-label, dose-optimization study. J Child Adolesc Psychopharmacol. 2009;19:649–662. doi: 10.1089/cap.2008.0165. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  17. Geurts HM. Verté S. Oosterlaan J. Roeyers H. Sergeant JA. How specific are executive functioning deficits in attention deficit hyperactivity disorder and autism? J Child Psychol Psychiatry. 2004;45:836–854. doi: 10.1111/j.1469-7610.2004.00276.x. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  18. Gioia GA. Isquith PK. Guy SC. Kenworthy L. BRIEF: Behavior Rating Inventory of Executive Function: Professional Manual. Lutz, FL: Psychological Assessment Resources, Inc.; 2000. [Google Scholar]
  19. Gioia GA. Isquith PK. Retzlaff PD. Espy KA. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol. 2002;8:249–257. doi: 10.1076/chin.8.4.249.13513. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  20. Houghton S. Douglas G. West J. Whiting K. Wall M. Langsford S, et al. Differential patterns of executive function in children with attention-deficit hyperactivity disorder according to gender and subtype. J Child Neurol. 1999;14:801–805. doi: 10.1177/088307389901401206. [DOI] [PubMed] [Google Scholar] · DOI
  21. Kratochvil CJ. Faries D. Vaughan B. Perwien A. Busner J. Saylor K, et al. Emotional expression during attention-deficit/hyperactivity disorders treatment: Initial assessment of treatment effects. J Child Adolesc Psychopharmacol. 2007;17:51–62. doi: 10.1089/cap.2006.0018. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  22. Lawrence V. Houghton S. Douglas G. Durkin K. Whiting K. Tannock R. Executive function and ADHD: A comparison of children's performance during neuropsychological testing and real-world activities. J Atten Disord. 2004;7:137–149. doi: 10.1177/108705470400700302. [DOI] [PubMed] [Google Scholar] · DOI
  23. Leroux JR. Turgay A. Quinn D. Advances in ADHD treatment. Can J Diagn. 2009;26:49–52. [Google Scholar]
  24. Mahone EM. Hoffman J. Behavior ratings of executive function among preschoolers with ADHD. Clin Neuropsychol. 2007;21:569–586. doi: 10.1080/13854040600762724. [DOI] [PubMed] [Google Scholar] · DOI
  25. Mares D. McLuckie A. Schwartz M. Saini M. Executive function impairments in children with attention-deficit hyperactivity disorder: Do they differ between school and home environments? Can J Psychiatry. 2007;52:527–534. doi: 10.1177/070674370705200811. [DOI] [PubMed] [Google Scholar] · DOI
  26. McCandless S. O'Laughlin L. The clinical utility of the Behavior Rating Inventory of executive function (BRIEF) in the diagnosis of ADHD. J Atten Disord. 2007;10:381–389. doi: 10.1177/1087054706292115. [DOI] [PubMed] [Google Scholar] · DOI
  27. McCracken JT. Biederman J. Greenhill LL. Swanson JM. McGough JJ. Spencer TJ, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42:673–683. doi: 10.1097/01.CHI.0000046863.56865.FE. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  28. McGough JJ. Biederman J. Wigal SB. Lopez FA. McCracken JT. Spencer T, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44:530–538. doi: 10.1097/01.chi.0000157550.94702.a2. [DOI] [PubMed] [Google Scholar] · DOI
  29. Miller EK. Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev Neurosci. 2001;24:167–202. doi: 10.1146/annurev.neuro.24.1.167. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  30. Pennington BF. Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry. 1996;37:51–87. doi: 10.1111/j.1469-7610.1996.tb01380.x. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  31. Perwien AR. Kratochvil CJ. Faries D. Vaughan B. Busner J. Saylor KE, et al. Emotional expression in children treated with ADHD medication: Development of a new measure. J Atten Disord. 2008;11:568–579. doi: 10.1177/1087054707306117. [DOI] [PubMed] [Google Scholar] · DOI
  32. Qian Y. Cao QJ. Wang YF. [Effect of extended-release methylphenidate on the ecological executive function for attention deficit hyperactivity disorder] Beijing Da Xue Xue Bao. 2007;39:299–303. [PubMed] [Google Scholar]
  33. Qian Y. Wang YF. [Reliability and validity of behavior rating scale of executive function parent form for school age children in China] Beijing Da Xue Xue Bao. 2007;39:277–283. [PubMed] [Google Scholar]
  34. Quraishi S. Frangou S. Neuropsychology of bipolar disorder: A review. J Affect Disord. 2002;72:209–226. doi: 10.1016/s0165-0327(02)00091-5. [DOI] [PubMed] [Google Scholar] · DOI
  35. Riccio CA. Homack S. Jarratt KP. Wolfe ME. Differences in academic and executive function domains among children with ADHD Predominantly Inattentive and Combined Types. Arch Clin Neuropsychol. 2006;21:657–667. doi: 10.1016/j.acn.2006.05.010. [DOI] [PubMed] [Google Scholar] · DOI
  36. Scheres A. Oosterlaan J. Geurts H. Morein-Zamir S. Meiran N. Schut H, et al. Executive functioning in boys with ADHD: Primarily an inhibition deficit? Arch Clin Neuropsychol. 2004;19:569–594. doi: 10.1016/j.acn.2003.08.005. [DOI] [PubMed] [Google Scholar] · DOI
  37. Steele M. Weiss M. Swanson J. Wang J. Prinzo RS. Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol. 2006;13:e50–e62. [PubMed] [Google Scholar]
  38. Sullivan JR. Riccio CA. Diagnostic group differences in parent and teacher ratings on the BRIEF and Conners' Scales. J Atten Disord. 2007;11:398–406. doi: 10.1177/1087054707299399. [DOI] [PubMed] [Google Scholar] · DOI
  39. Verté S. Geurts HM. Roeyers H. Oosterlaan J. Sergeant JA. Executive functioning in children with autism and Tourette syndrome. Dev Psychopathol. 2005;17:415–445. doi: 10.1017/s0954579405050200. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  40. Wiersema JR. Roeyers H. ERP correlates of effortful control in children with varying levels of ADHD symptoms. J Abnorm Child Psychol. 2009;37:327–336. doi: 10.1007/s10802-008-9288-7. [DOI] [PubMed] [Google Scholar] · DOI
  41. Wodka EL. Mostofsky SH. Prahme C. Gidley Larson JC. Loftis C. Denckla MB, et al. Process examination of executive function in ADHD: Sex and subtype effects. Clin Neuropsychol. 2008;22:826–841. doi: 10.1080/13854040701563583. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page

Authors
Turgay, A., Ginsberg, L., Sarkis, E., Jain, R., Adeyi, B., Gao, J., Dirks, B., Babcock, T., Scheckner, B., Richards, C., Lasser, R., & Findling, R. L.
Affiliations
  • University of Toronto (CA)
  • Red Oak Psychiatry Associates, Houston, Texas.
  • Sarkis Clinical Trials, Gainesville, Florida.
  • R/D Clinical Research, Inc., Lake Jackson, Texas.
  • Takeda (United States) (US)
  • University Hospitals Cleveland Medical Center (US)
Corresponding author
Findling, Robert L.
ORCID
Venue
Journal of Child and Adolescent Psychopharmacology
Publisher
SAGE Publications
Published
2010-12
Volume
20
Issue
6
Pages
503-511
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
DOI
10.1089/cap.2009.0110
PMC
PMC3005278
OpenAlex
W2046461248
Cited by
23
References
53
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2014: 2 · 2013: 3 · 2012: 5
FWCI
1.75
Type
journal article
Language
en
Open access
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations
  • Journal of Child and Adolescent Psychopharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Purdue University
  • University of Ottawa
  • Jazz Pharmaceuticals
  • Neurocrine Biosciences
  • Supernus Pharmaceuticals
  • Purdue Pharma
  • Hospital for Sick Children
  • H. Lundbeck A/S
  • Medical Research Council
  • UCB Pharma
  • Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
lisdexamfetamine dimesylate, attention deficit hyperactivity disorder, executive function, children, long-acting stimulants, BRIEF, ADHD Rating Scale-IV, treatment-emergent adverse events, ADHD subtypes, comorbid psychiatric symptoms, dose optimization
MeSH terms
Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Dextroamphetamine, Dose-Response Relationship, Drug, Female, Humans, Male, Neuropsychological Tests, Prospective Studies, Psychometrics, Executive Function

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review